Abstracts

Skip to Late-Breaking Abstracts »

Poster Presentation Dates

All odd numbered posters will be presented on Friday, November 8, 2019, while even numbered posters will be presented on Saturday, November 9, 2019.

Posters will be on display from 7 a.m. - 8 p.m., with the presenting authors required to be at their posters during lunch (12:30 - 2 p.m. on Friday, Nov. 8, and 12:35 - 2:05 p.m. on Saturday, Nov. 9) and also during the poster reception (6:30 - 8p.m. on Friday, Nov. 8, and 7 - 8:30 p.m. on Saturday, Nov. 9).


Search word or phrase:

# Title Authors Category Keywords
O63 Gastric toxicity associated with PD-1 blockade therapy revealed by Multiplexed Ion Beam Imaging Selena Ferrian, PhD; Theodore S. Nowicki, MD, PhD; David W. Dawson; Alex Baranski; John Glaspy, MD; Antoni Ribas, MD, PhD; Michael Angelo, MD, PhD; Immunotherapy Toxicities Autoimmunity; Checkpoint blockade; Inflammation; Systems biology
O64 Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease Hamzah Abu-Sbeih, MD; David Faleck; Biagio Ricciuti, MD; Robin Mendelsohn; Abdul Rafeh Naqash, MD; Justine V. Cohen, DO; MacLean C. Sellars; Aanika Balaji; Guy Ben-betzalel; Ibraheim Hajir; Jiajia Zhang, MD, MPH; Mark Awad, MD PhD; Giulia Leonardi; Douglas B. Johnson, MD, MSCI; David J. Pinato, MD, MRes, PhD; Dwight Owen; Sarah A. Weiss, MD; Giuseppe Lamberti, MD; Mark Lythgoe; Lisa Manuzzi; Christina Arnold; Wei Qiao, PhD; Jarushka Naidoo, MD; Gal Markel; Nick Powell; Sai-Ching J. Yeung, MD, PhD; Elad Sharon, MD, MPH; Michael Dougan, MD, PhD; Yinghong Wang, MD, PhD; Immunotherapy Toxicities Autoimmunity; Checkpoint blockade; Immune suppression; Immune toxicity; Inflammation
P708 Real world evidence of patient clinical profiles with advanced solid tumor malignancies receiving immune checkpoint inhibitors to investigate potential predictors for immune-related adverse events. Stephanie Berg, DO; Joseph I. Clark, MD; Jose Guevara; Elizabeth Elliott, DO; Stephanie Berg, DO; Stephanie Berg, DO; Michael Wesolowski; Blaine Knox, MD; Daniel Linden, DO; Courtney Wagner, MD; Immunotherapy Toxicities Biomarkers; Checkpoint blockade; Clinical study; Immune toxicity; Solid tumors
P709 Immunotherapy Adverse Events Predict Treatment Response Diana V. Maslov; Katherine Thomas, MD, MS; Victoria Simenson, MD; Caitlin Sullivan, MD; Alaa Mohammed, MPH; Jessica Boyce; Jonathan Lu, MD; John Kucharczyk, MD; Marc R. Matrana; Immunotherapy Toxicities Checkpoint blockade; Immune tolerance; Immune toxicity; Solid tumors; Targeted therapy
P710 Immune Checkpoint Inhibitors increase the risk of Hypothyroidism in Patients with Primary Head and Neck Cancer Compared to Other Cancers Omar A. Alaber, MD; Apoorva K. Chandar; Prateek Mendiratta, MD; Monaliben Patel, MD; Chris J. Hoimes, MD; Pierre Lavertu, MD; Ankit Mangla, MD Immunotherapy Toxicities Checkpoint blockade; Epidemiology; Immune toxicity; Radiotherapy; Solid tumors; Targeted therapy
P711 Single-Center Analysis of Safety and Efficacy of Immune Checkpoint Inhibitors (ICI) in Non-Hematologic Malignancies: Effects of Age and Eosinophilia Justin T. Moyers, MD; Dhanu Desai; Jasmine Mitchell; Jeffrey Ahn; Steven Hardin; Mie Mie Thinn; Immunotherapy Toxicities Checkpoint blockade; Immune monitoring; Immune toxicity
P712 Conditional immune toxicity rate with immune checkpoint inhibitors Pier Vitale Nuzzo, MD, PhD; Gregory Russell Pond, M.Sc, PhD; Amin Nassar, MD; Sarah Abou Alaiwi, MD; Ronan Flippot, MD; Catherine Curran; Kerry Kilbridge, MD; Xiao Wei, MD; Bradley Mcgregor, MD; Lauren Harshman, MD; Toni K. Choueiri; Guru Sonpavde, MD; Immunotherapy Toxicities Biomarkers; Checkpoint blockade; Immune monitoring; Immune toxicity; Targeted therapy
P714 Immunological features of immune-related adverse events during anti-PD-1/PD-L1 immune checkpoint inhibition Meghali Goswami, MPhil; Gege Gui; Katherine E. Lindblad; Jaydira Del Rivero, MD; Jennifer Marte, BS MD; Pradeep K. Dagur, PhD; Christin B. Destefano, MD; Julie Thompson, RN; Bogdan Popescu, MD; Laura Dillon, PhD; Cheryl D. Johnson; Steven J. Soldin, PhD; Catherine Lai, MD, MPH; James L. Gulley, MD, PhD, FACP; Christopher S. Hourigan, MD, PhD; Immunotherapy Toxicities Autoimmunity; Checkpoint blockade; Clinical study; Clinical trial; Gene expression; Immune toxicity; Leukemia/Lymphoma; T cell
P715 Strategies to mitigate immune-related adverse events of efficacious combination immunotherapies in preclinical models of cancer Célia Jacoberger-Foissac, PhD; Stephen J. Blake; Célia Jacoberger-Foissac, PhD; Jing Liu; Stacey Allen; Juming Yan; Heidi Harjunpaa; Mark J. Smyth; Michele W. Teng, PhD; Immunotherapy Toxicities Antibody; Autoimmunity; Cytokine; Immune suppression; Immune toxicity; Regulatory T cell (Treg cell); Solid tumors
P716 An In Vivo PBMC Humanized Mouse Model for Determining Checkpoint and Bispecific Antibody Treatment Related Cytokine Release Syndrome Chunting Ye; Mingshan Cheng; Michael Brehm; Dale Greiner; Leonard Shultz; James Keck, PhD; Immunotherapy Toxicities Checkpoint blockade; Cytokine; Immune toxicity
P717 Involvement of IL17 in a case of fatal neuroendocrine toxicity associated with dual immune checkpoint blockade Luca Mazzarella, MD PhD; Silvia Giugliano; Paolo D'Amico; Carmen Belli; Bruno Duso; Giuseppe Curigliano, MD, PhD; Maria Rescigno, MD, PhD; Luca Mazzarella, MD PhD; Immunotherapy Toxicities Checkpoint blockade; Cytokine; Dendritic cell; Immune toxicity
P718 A case of dual-mechanism hematologic immune-related adverse event in a patient with metastatic melanoma treated with combined nivolumab and ipilimumab Daniel J. Olson, MD; Melissa Tjota, MD, PhD; Padma Rajagopal, MD; Girish Venkataraman, MD; Jason J. Luke, MD, FACP; Thomas F. Gajewski, MD, PhD; Immunotherapy Toxicities Autoimmunity; Checkpoint blockade; Immune toxicity
P719 CD8+ Tcell integrin α4β7expression: a potential predictor of severity and steroid sensitivity in checkpoint inhibitor induced colitis Anna C. Olsson-Brown, MBChB (Hons), BSc (Hons); Joseph Sacco, MSc, MBChB, MRCP, Ph; Sandra CP. Cachinho; Carol Jolly; Vanessa Fontana; Rosemary Lord; Mark Coles; Munir Pirmohamed; Immunotherapy Toxicities Immune toxicity; Inflammation; Solid tumors; T cell
P720 The use of in vitro assays to reduce the risk of unwanted immunogenicity Amin Osmani; Thibault Jonckheere; Sofie Pattijn; Mayuko Oh; Thibaut Janss; Immunotherapy Toxicities Dendritic cell; Immune suppression; Immune tolerance; Immune toxicity; Monocyte/Macrophage; Myeloid cells; MDSC; Regulatory T cell (Treg cell); T cell
P721 Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis Hamzah Abu-Sbeih, MD; Lauren N. Herrera; Tenglong Tang, MD; Mehmet Altan; Anne-Maria P. Chaftari; Pablo C. Okhuysen; Robert Jenq, MD; Yinghong Wang, MD, PhD; Immunotherapy Toxicities Autoimmunity; Checkpoint blockade; Immune toxicity; Inflammation; Microbiome
P722 Opportunistic Infection Outcomes in Patients Receiving Corticosteroids for Immune Checkpoint Inhibitor Toxicity Michael R. Cook, MD; Michael B. Atkins, MD; Immunotherapy Toxicities Checkpoint blockade; Immune suppression; Immune toxicity
P723 Interleukin-6 blockade to de-couple CTLA-4 blockade colitis from anti-tumor efficacy Yared Hailemichael, PhD; Daniel H. Johnson, MD; Wai C. Foo; Kenneth R. Hess, BS, MS, PhD; Cara Haymaker, PhD; Chantal M. Saberian, MD; Salah E. Bentebibel; Elizabeth Burton; Yinghong Wang, MD, PhD; Scott Woodman; Patrick Hwu, MD; Adi Diab, MD; Immunotherapy Toxicities Autoimmunity; Checkpoint blockade; Chemokine; Cytokine; Immune toxicity; Inflammation; Monocyte/Macrophage; Myeloid cells; T cell; Tumor infiltrating lymphocytes (TILs)
P724 Analysis of healthcare provider management of immune-related adverse events and concordance with NCCN Guidelines® Megan Cartwright, PhD; Krista Marcello, BA; Jillian L. Scavone, PhD; Kevin L. Obholz, PhD; Timothy A. Quill, PhD; John A. Thompson; Immunotherapy Toxicities Autoimmunity; Checkpoint blockade; Immune toxicity
P725 Clinical features of immune checkpoint inhibitor-related adrenal insufficiency: a retrospective analysis Qinwen Zhou, MD; Sandip P. Patel, MD; Qinwen Zhou, MD; Vala Hamidi; Qinwen Zhou, MD; Immunotherapy Toxicities Autoimmunity; Checkpoint blockade; Immune monitoring; Immune toxicity; Solid tumors